 
MAINE STATE LEGISLATURE  
 
 
 
The following document is provided by the 
LAW AND LEGISLATIVE DIGITAL LIBRARY  
at the Maine State Law and Legislative Reference Library 
http://legislature.m aine.gov/lawlib 
 
 
 
 
 
 
 
 
 
 
Reproduced from electronic originals 
(may include minor formatting diffe rences from printed original) 
 
 
Printed on recycled paper128th MAINE LEGISLATURE
FIRST REGULAR SESSION-2017
Legislative Document No. 114
H.P. 82 House of  Representatives, January 17, 2017
An Act  To Increase the Number of Suboxone Prescribers
Reference to the Committee on Labor, Commerce, Research and Economic  Development 
suggested and ordered printed.
ROBERT  B. HUNT
Clerk
Presented by Representative MADIGAN of Waterville.
Cosponsored by Senator BREEN of  Cumberland  and Representatives: AUSTIN  of 
Skowhegan, DOORE  of Augusta, McCREIGHT  of Harpswell, O'NEIL of Saco, RYKERSON 
of Kittery, SPEAR of South Thomaston, TIPPING of Orono,  WARREN of Hallowell.

 
 Page 1 - 128LR0409(01) -1 
 Be it enacted by the People of the State of Maine as follows:  1 
Sec. 1.  32 MRSA §2594 -E, sub -§5, ¶D, as enacted by PL 2015, c. 242, §3, is 2 
amended to read:  3 
D.  Scope of practice for physician assistants, including prescribing of controlled 4 
drugs and treatin g opioid dependency with buprenorphine products ; 5 
Sec. 2.  32 MRSA §2594 -E, sub -§6 is enacted to read:  6 
6.  Waiver application for buprenorphine.   A physician assistant licensed and 7 
registered pursuant to this section whose scope of practice includes prescri bing opioid 8 
medication and who is authorized under federal law to be eligible for a waiver from the 9 
federal Drug Enforcement Administration for treating opioid dependency with 10 
buprenorphine products shall apply for the waiver for the purpose of treating op ioid 11 
dependency with buprenorphine products.  12 
Sec. 3.  32 MRSA §2600 -D is enacted to read:  13 
§2600 -D.  Waiver application for buprenorphine  14 
An individual licensed under this chapter whose scope of practice includes 15 
prescribing opioid medication shall obtain a  physician waiver from the federal Drug 16 
Enforcement Administration for the purpose of treating opioid dependency with 17 
buprenorphine products.   18 
Sec. 4.  32 MRSA §3270 -E, sub -§5, ¶D, as enacted by PL 2015, c. 242, §5, is 19 
amended to read:  20 
D.  Scope of practi ce for physician assistants, including prescribing of controlled 21 
drugs and treating opioid dependency with buprenorphine products ; 22 
Sec. 5.  32 MRSA §3270 -E, sub -§6 is enacted to read:  23 
6.  Waiver application for buprenorphine.   A physician assistant license d and 24 
registered pursuant to this section whose scope of practice includes prescribing opioid 25 
medication and who is authorized under federal law to be eligible for a waiver from the 26 
federal Drug Enforcement Administration for treating opioid dependency wit h 27 
buprenorphine products shall apply for the waiver for the purpose of treating opioid 28 
dependency with buprenorphine products.  29 
Sec. 6.  32 MRSA §3300 -G is enacted to read:  30 
§3300 -G.  Waiver application for buprenorphine  31 
An individual licensed under this cha pter whose scope of practice includes 32 
prescribing opioid medication shall obtain a physician waiver from the federal Drug 33 
Enforcement Administration for the purpose of treating opioid dependency with 34 
buprenorphine products.   35 
 
 Page 2 - 128LR0409(01) -1 
 Sec. 7.  MaineCare reimburseme nt rates for buprenorphine -medication - 1 
assisted treatment of substance use disorder.   The Department of Health and 2 
Human Services shall increase reimbursement rates under the MaineCare program for 3 
buprenorphine -medication -assisted treatment, including presc riptions and accompanying 4 
behavioral health services, such as case management, counseling and drug testing, by 5 
30% no later than January 1, 2018.  6 
SUMMARY  7 
This bill requires osteopathic and allopathic physicians whose scope of practice 8 
includes prescribing opioid medication to obtain a physician waiver from the federal 9 
Drug Enforcement Administration to treat opioid dependency using buprenorphine 10 
products.  It also requires physician assistants whose scope of practice includes 11 
prescribing opioid medication t o apply for a waiver as long as they are authorized under 12 
federal law.  The bill also requires the Department of Health and Human Services to 13 
increase reimbursement rates under the MaineCare program for buprenorphine - 14 
medication -assisted treatment including  prescriptions and accompanying services by 30% 15 
no later than January 1, 2018.  16 
 
